Sponsored Links
| NICE Issues Positive Final Appraisal Determination Recommending The Use Of Basilea's Toctino |
 |
 |
 |
| Medical News - Dermatology | |||
|
Basilea Pharmaceutica Ltd. (SWISS: BSLN) announces that the National Institute for Health and Clinical Excellence (NICE) issued the Final Appraisal Determination (FAD) recommending the use of Toctino® (alitretinoin) within its licensed indication, as a treatment option for adults with severe chronic hand eczema that has not responded to potent topical corticosteroids. Read more: Dermatology News From Medical News Today
|